ライフサイエンスコーパス: neuroprotective drug

1 rotection warranting its clinical trial as a neuroprotective drug.

2 nt with antibiotics, anti-edema measures and neuroprotective drugs.

3 ially enhance the future assessment of novel neuroprotective drugs.

4 made between the effectiveness of potential neuroprotective drugs.

5 nical and clinical research identified three neuroprotective drugs acting on different axonal pathobi

6 herapeutic candidates for the development of neuroprotective drugs against AD.

7 cascade has helped stimulate development of neuroprotective drugs aimed at limiting brain injury in

8 performed an initial screening for potential neuroprotective drugs among a group of flavonoids by usi

9 ted to hyperkalemia and opioid toxicity, and neuroprotective drugs, among others.

10 proach to identify ethoxyquin as a potential neuroprotective drug and carried out additional biochemi

11 cline is an established antiinflammatory and neuroprotective drug and may provide a novel approach to

12 ted imaging evaluation) and therapeutic (eg, neuroprotective drugs and treatments for haemorrhagic st

13 Lessons learned from failed trials of neuroprotective drugs are being used to design new trial

14 orting evidence, Chinese herbal products and neuroprotective drugs are widely used, and the increased

15 he failure of current analgesics and suggest neuroprotective drugs as appropriate strategies to treat

16 ms and for identifying potential targets for neuroprotective drugs at pre-clinical stages.

17 ss whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) cou

18 Thus, AUTEN-99 serves as a potent neuroprotective drug candidate for preventing and treati

19 Therefore, NALL is a promising novel, neuroprotective drug candidate for the treatment of TBI.

20 to compare the treatment effects of putative neuroprotective drug candidates following neonatal hypox

21 might offer a new approach in the design of neuroprotective drug candidates.

22 The use of more refined outcomes and truly neuroprotective drugs, coupled with more efficient trial

23 Here we show that ATP and the neuroprotective drug dexpramipexole (DEX) inhibited an i

24 (Li) has garnered considerable interest as a neuroprotective drug for a broad range of nervous system

25 cal trials encourage exploration of NBP as a neuroprotective drug for the treatment of ischemic strok

26 rimental and clinical research to identify a neuroprotective drug for the treatment of traumatic brai

27 usceptible to SARS-CoV-2, identify candidate neuroprotective drugs for COVID-19 patients, and suggest

28 tetrahydropyridine (MPTP) models to identify neuroprotective drugs for Parkinson's disease (PD).

29 may allow patients to take advantage of this neuroprotective drug in chronic neurodegenerative diseas

30 Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's diseas

31 The failure of most neuroprotective drugs in clinical trials has been due to

32 ns and may represent an important target for neuroprotective drugs in degenerative diseases involving

33 on the potential targets for development of neuroprotective drugs in Parkinson's disease and suggest

34 ess of several antiepileptic, analgesic, and neuroprotective drugs is attributable to state-dependent

35 ology and the development of new multitarget neuroprotective drugs is promising and attractive.

36 the future, combinations of thrombolytic and neuroprotective drugs may be used to attempt maximum rat

37 Neuroprotective drugs may be useful as an adjunct approa

38 hods for assessing the potential benefits of neuroprotective drugs on RGCs which have been injured by

39 erapy to either minimize neuronal death with neuroprotective drugs or to enhance spontaneous recovery

40 C-099, our brain-penetrant anti-inflammatory neuroprotective drug, prevented inflammatory endothelial

41 We show that the neuroprotective drug riluzole increased the amount of HS

42 alcium increases and can be activated by the neuroprotective drug riluzole.

43 Third, neuroprotective drugs should be tested in combination wi

44 state affinity or use-dependent block by the neuroprotective drug sipatrigine (compound 619C89).

45 PD has permitted the development of putative neuroprotective drugs that might slow or stop disease pr

46 ulating agent alone or in combination with a neuroprotective drug to symptomatic SOD1G93A mice reduce

47 tion in AD increases, it is anticipated that neuroprotective drugs to slow or prevent neuronal dysfun

48 and identify targets for the development of neuroprotective drugs, we developed a high-throughput RN

49 tion of Neotrofin, a cognitive-enhancing and neuroprotective drug, with the heme oxygenase system.